HSCL2023-07-012023-09-30 HSCL2023-07-012023-09-30 HSCL2023-07-012023-09-30in-bse-fin:OneOperatingExpenses01Member HSCL2023-07-012023-09-30in-bse-fin:FourOperatingExpenses01Member HSCL2023-09-30 HSCL2023-07-012023-09-30in-bse-fin:OneReportableSegmentRevenue01Member HSCL2023-07-012023-09-30in-bse-fin:OneReportableSegmentRevenue02Member HSCL2023-07-012023-09-30in-bse-fin:FourReportableSegmentRevenue01Member HSCL2023-07-012023-09-30in-bse-fin:FourReportableSegmentRevenue02Member HSCL2023-07-012023-09-30in-bse-fin:OneReportableSegmentResults01Member HSCL2023-07-012023-09-30in-bse-fin:OneReportableSegmentResults02Member HSCL2023-07-012023-09-30in-bse-fin:FourReportableSegmentResults01Member HSCL2023-07-012023-09-30in-bse-fin:FourReportableSegmentResults02Member HSCL2023-07-012023-09-30in-bse-fin:OneReportableSegmentAssets01Member HSCL2023-07-012023-09-30in-bse-fin:OneReportableSegmentAssets02Member HSCL2023-07-012023-09-30in-bse-fin:OneReportableSegmentLiabilities01Member HSCL2023-09-30in-bse-fin:OneReportableSegmentLiabilities01Member HSCL2023-07-012023-09-30in-bse-fin:OneReportableSegmentLiabilities02Member HSCL2023-09-30in-bse-fin:OneReportableSegmentLiabilities02Member HSCL2023-07-012023-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member HSCL2023-07-012023-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member HSCL2023-07-012023-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member HSCL2023-07-012023-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member HSCL2023-07-012023-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member HSCL2023-07-012023-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500184 HSCL NA Himadri Speciality Chemical Limited Equity 2023-04-01 2024-03-31 2023-10-17 2023-10-10 INR Crores Half yearly 17:30:00 18:45:00 2023-10-17 2023-10-17 true Cash Flow Indirect Not applicable Multi segment 2023-07-01 2023-09-30 Unaudited Consolidated 10045200000.00 98200000.00 10143400000.00 7502300000.00 0.00 -256400000.00 282200000.00 159500000.00 124300000.00 940500000.00 8752400000.00 1391000000.00 0.00 1391000000.00 244200000.00 140600000.00 384800000.00 0.00 1006200000.00 0.00 0.00 0.00 0.00 1006200000.00 -38800000.00 967400000.00 1006400000.00 -200000.00 967900000.00 -500000.00 440000000.00 1 2.29 2.29 0.00 0.00 2.29 2.29 (2) The above unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 17 October 2023. A Limited Review of these consolidated financial results for the quarter and six months ended 30 September 2023 has been carried out by the Statutory Auditors, as required under Regulation 33 of SEBI (LODR) Regulations, 2015. (3) Other expenses includes foreign exchange fluctuation loss/ (gain) (net) of Rs (1.21) crore for the quarter ended 30 September 2023, Rs (4.11) crores for the quarter ended 30 June 2023, Rs 5.54 crores for the quarter ended 30 September 2022, Rs (5.32) crores for the six months ended 30 September 2023, Rs 19.17 crores for the six months ended 30 September 2022 and Rs 19.80 crores for the year ended 31 March 2023, on consolidated basis. Finance cost includes exchange difference regarded as an adjustment to borrowing costs in accordance with Ind AS 23, of Rs 1.61 crores for the quarter ended 30 September 2023, Re 0.50 crore for the quarter ended 30 June 2023, Rs 6.13 crores for the quarter ended 30 September 2022, Rs 2.11 crores for the six months ended 30 September 2023, Rs 10.68 crores for the six months ended 30 September 2022 and Rs 13.50 crores for the year ended 31 March 2023, on consolidated basis. (4) Based on the guiding principles given in Ind AS 108 on 'Operating Segments', the Group's business activity falls within two operating segments, namely: (a) Carbon materials and chemicals, and (b) Power (5) The consolidated financial results are prepared in accordance with the principles and procedures for the preparation and presentation of consolidated financial results as set out in Ind AS 110 'Consolidated Financial Statements' notified by Ministry of Corporate Affairs. The consolidated financial results of Himadri Speciality Chemical Limited (the Holding Company or the Parent), include its subsidiaries, namely AAT Global Limited, Shandong Dawn Himadri Chemical Industry Limited and Combe Projects Private Limited (w.e.f 20 July 2023) (the Holding Company or the Parent and its subsidiaries together referred to as the 'Group'), combined on a line-by-line basis by adding together the book values of like items of asset and liabilities, income and expenses eliminating intra-group balances and transactions and resulting unrealised gains/ (losses). The consolidated financial results are prepared applying uniform accounting policies on all material items. Multi segment 2023-04-01 2023-09-30 Unaudited Consolidated 19554300000.00 199400000.00 19753700000.00 14456300000.00 0.00 -201800000.00 540000000.00 291000000.00 245300000.00 1843100000.00 17173900000.00 2579800000.00 0.00 2579800000.00 454600000.00 258000000.00 712600000.00 0.00 1867200000.00 0.00 0.00 0.00 0.00 1867200000.00 447100000.00 2314300000.00 1867900000.00 -700000.00 2313700000.00 600000.00 440000000.00 1 4.28 4.28 0.00 0.00 4.28 4.28 Other Expenses 940500000.00 Other Expenses 1843100000.00 -27500000.00 15134500000.00 661100000.00 0.00 250100000.00 2724600000.00 101300000.00 10000000.00 2592400000.00 5428300000.00 73300000.00 198200000.00 21745500000.00 8419200000.00 0.00 5738100000.00 441900000.00 2116200000.00 19600000.00 165500000.00 8481300000.00 3714400000.00 20614900000.00 42360400000.00 440000000.00 24997900000.00 25437900000.00 25410400000.00 280200000.00 40400000.00 320600000.00 58400000.00 1329900000.00 1708900000.00 10014200000.00 4323600000.00 218900000.00 14556700000.00 566700000.00 20500000.00 97200000.00 15241100000.00 16950000000.00 42360400000.00 (6) During the previous year, the Holding Company has issued and allotted 72,550,000 warrants, each convertible into one equity share of Re 1 each, on Preferential allotment basis at an issue price of Rs 70 per warrant, to the Promoter/ Promoter Group of the Holding Company and certain identified non-promoter persons / entity, upon receipt of 25% of the issue price (i.e. Rs 17.50 per warrant) as warrant subscription money. Balance 75% of the issue price (i.e. Rs 52.50 per warrant) shall be payable within 18 months from the date of allotment i.e.22 August 2022, at the time of exercising the option to apply for fully paid-up equity share of Re 1 each of the Holding Company, against each warrant held by the warrant holder. During the quarter ended 30 September 2023, the Holding Company upon receipt of balance 75% of the issue price (i.e., Rs 52.50 per warrant) for 463,000 warrants, has allotted equal no. of fully paid-up equity shares against conversion of said warrants exercised by the warrant holder. As a result of such allotment, the paid-up equity share capital of the Holding Company has increased from 438,995,659 equity shares to 439,458,659 equity shares of face value of Re 1 each. For the remaining 52,572,000 warrants, the respective allottees have not yet exercised their option for conversion of the warrants into equity shares and accordingly, balance 75% money towards such remaining warrants is yet to be received. The last day for exercising the option for conversion of the warrants into equity shares of the Holding Company is 21 February 2024, being 18 months from the date of allotment of warrants i.e., 22 August 2022. (7) The Nomination and Remuneration Committee of the Holding Company at its meeting held on 22 September 2023, has allotted 563,914 equity shares of Re 1 each (Under Grant I: 29,561 equity shares and under Grant II: 534,353 equity shares) to the option grantees pursuant to exercise of options under the Holding Company’s “Himadri Employee Stock Option Plan 2016”. As a result of such allotment, the paid up equity share capital of the Holding Company has increased from 439,458,659 equity shares to 440,022,573 equity shares of face value of Re 1 each. (8) Earnings per share is not annualised for the quarter ended 30 September 2023, 30 June 2023, 30 September 2022, six months ended 30 September 2023 and 30 September 2022. (9) The figures of the corresponding previous periods/year have been regrouped/reclassified, wherever necessary, to conform to the classification for the current quarter ended 30 September 2023. Statement of Cash Flows has been prepared under the indirect method as set out in Ind AS 7 Statement of Cash Flows . Carbon materials and chemicals 9987700000.00 Power 254900000.00 Carbon materials and chemicals 19439100000.00 Power 513100000.00 10242600000.00 19952200000.00 197400000.00 397900000.00 10045200000.00 19554300000.00 Carbon materials and chemicals 1213500000.00 Power 226700000.00 Carbon materials and chemicals 2159500000.00 Power 458700000.00 1440200000.00 2618200000.00 159500000.00 291000000.00 -110300000.00 Other unallocable expenses net of unallocable income includes other income, foreign exchange loss/ (gain) (net), and exceptional items fully unallocable. -252600000.00 1391000000.00 2579800000.00 Carbon materials and chemicals 33535300000.00 Power 1097200000.00 34632500000.00 7727900000.00 42360400000.00 Carbon materials and chemicals 5176900000.00 Power 2300000.00 5179200000.00 11770800000.00 16950000000.00 291000000.00 -2977100000.00 -662900000.00 0.00 -8100000.00 700000.00 0.00 -2156300000.00 0.00 860100000.00 0.00 -239500000.00 0.00 245300000.00 0.00 0.00 0.00 -42300000.00 0.00 -44800000.00 0.00 161200000.00 0.00 0.00 0.00 0.00 0.00 15200000.00 0.00 -4879900000.00 -2300100000.00 0.00 361400000.00 0.00 0.00 0.00 -2661500000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 800000.00 336800000.00 2328100000.00 3131100000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 206100000.00 0.00 800000.00 0.00 -932100000.00 0.00 0.00 427400000.00 0.00 0.00 0.00 0.00 0.00 2123300000.00 226100000.00 0.00 6100000.00 108200000.00 289100000.00 0.00 36300000.00 1957500000.00 -1636100000.00 0.00 -1636100000.00 2078000000.00 441900000.00 Remeasurement of the net defined benefit plan -500000.00 Net gain/(loss) on investment in equity instruments accounted at fair value -61200000.00 Remeasurement of the net defined benefit plan -1000000.00 Net gain/(loss) on investment in equity instruments accounted at fair value 594400000.00 -61700000.00 593400000.00 -18300000.00 132300000.00 Exchange difference in transalating financial statements of foreign operations 4600000.00 Exchange difference in transalating financial statements of foreign operations -14000000.00 4600000.00 -14000000.00 0.00 0.00